We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Halozyme Therapeutics, Inc. (HALO - Free Report) reported fourth-quarter 2020 earnings of 50 cents per share, which missed the Zacks Consensus Estimate of 56 cents. The company had reported a loss of 17 cents in the year-ago quarter.
Total revenues increased 126.6% year over year to $121.7 million primarily driven by an upfront payment from Horizon Therapeutics and a milestone payment from J&J (JNJ - Free Report) . The top line also beat the Zacks Consensus Estimate of $119.72 million.
Quarterly Highlights
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues were $32 million in the fourth quarter, up 85.7% from the year-ago quarter, mainly driven by strong sales uptake of J&J’s subcutaneous Darzalex (Darzalex SC) and Roche’s (RHHBY - Free Report) Phesgo. However, royalties were hurt by lower sales of its mature legacy partner product.
Product sales, solely from the sale of bulk rHuPH20 to collaborators using the ENHANZE platform for drug development, increased 43% to $32.5 million in the fourth quarter. The increase was driven by strong demand for rHuPH20 from partners to support their commercial as well as under developing products.
Revenues under collaborative agreements were $57.3 million compared with $13.7 million in the prior-year quarter. The significant increase was due to the company’s recognition of $30 million in upfront payment from Horizon Therapeutics and $15 million in sales milestone from Janssen, a subsidiary of J&J. Halozyme inked an agreement with Horizon Therapeutics granting access to its ENHANZE platform during the quarter. Janssen’s payment was triggered following first commercial sale of Darzalex Faspro.
Research and development (R&D) expenses declined 83.6% year over year to $7.4 million mainly due to discontinuation of oncology drug development efforts.
Selling, general and administrative (SG&A) expenses were $10.4 million, down 56.4% from the year-ago period. The decline was due to lower compensation and commercial-related expenses as a result of a restructuring initiatives announced last year.
The company repurchased its own common stock worth $150 million during the fourth quarter.
Full-Year Results
Halozyme reported revenues of $267.6 million in 2020, up 36.5% year over year. The company’s earnings in 2020 were 91 cents per share against a loss of 50 cents per share in the year-ago period.
Business Developments
During the quarter, Halozyme’s two partners — Roche and argenx — initiated two late-stage studies on their respective pipeline candidates using ENHANZE technology. Halozyme received $32 million following the initiation of these studies. Meanwhile, the European Commission approved Roche's Phesgo for the treatment of patients with early and metastatic HER2-positive breast cancer in December.
Two late-stage studies were initiated by argenx in January and February. Janssen received accelerated approval from the FDA for a combination regimen of Darzalex Faspro for the treatment of adult patients with newly diagnosed light chain ("AL") amyloidosis in the last month. Regulatory applications for subcutaneous formulation of Darzalex was submitted by Janssen to the FDA and the European Medicine Agency in November last year seeking approval as treatment for relapsed or refractory multiple myeloma in second or later-line settings.
In November, Halozyme signed a global collaboration and license agreementwith Horizon Therapeutics, granting the latter access to its ENHANZE technology to develop the SC formulation of Horizon Therapeutics’ thyroid eye disease drug, Tepezza.
2021 Guidance Issued
Halozyme issued its guidance for revenues and earnings for 2021. The company expects total revenues in 2021 to be between $375 million and $395 million, indicating year-over-year growth of 40%-48%. The company expects revenues from royalties to double year over year on the back of strong uptake of subcutaneous formulation of J&J’s Darzalex.
It expects earnings to be in the range of $1.40-$1.55 per share.
The Zacks Consensus Estimates for revenues and earnings for 2021 stands at $405.49 million and $1.62 per share, respectively. This suggests that the company’s guidance for both earnings and revenues are below market expectations.
Shares of Halozyme were down 5.7% in after-market trading on Feb 23, following the earnings miss and dismal 2021 guidance. However, the stock has gained 144.3% in the past year compared with the industry’s 11.4% increase.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls
Halozyme Therapeutics, Inc. (HALO - Free Report) reported fourth-quarter 2020 earnings of 50 cents per share, which missed the Zacks Consensus Estimate of 56 cents. The company had reported a loss of 17 cents in the year-ago quarter.
Total revenues increased 126.6% year over year to $121.7 million primarily driven by an upfront payment from Horizon Therapeutics and a milestone payment from J&J (JNJ - Free Report) . The top line also beat the Zacks Consensus Estimate of $119.72 million.
Quarterly Highlights
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues were $32 million in the fourth quarter, up 85.7% from the year-ago quarter, mainly driven by strong sales uptake of J&J’s subcutaneous Darzalex (Darzalex SC) and Roche’s (RHHBY - Free Report) Phesgo. However, royalties were hurt by lower sales of its mature legacy partner product.
Product sales, solely from the sale of bulk rHuPH20 to collaborators using the ENHANZE platform for drug development, increased 43% to $32.5 million in the fourth quarter. The increase was driven by strong demand for rHuPH20 from partners to support their commercial as well as under developing products.
Revenues under collaborative agreements were $57.3 million compared with $13.7 million in the prior-year quarter. The significant increase was due to the company’s recognition of $30 million in upfront payment from Horizon Therapeutics and $15 million in sales milestone from Janssen, a subsidiary of J&J. Halozyme inked an agreement with Horizon Therapeutics granting access to its ENHANZE platform during the quarter. Janssen’s payment was triggered following first commercial sale of Darzalex Faspro.
Research and development (R&D) expenses declined 83.6% year over year to $7.4 million mainly due to discontinuation of oncology drug development efforts.
Selling, general and administrative (SG&A) expenses were $10.4 million, down 56.4% from the year-ago period. The decline was due to lower compensation and commercial-related expenses as a result of a restructuring initiatives announced last year.
The company repurchased its own common stock worth $150 million during the fourth quarter.
Full-Year Results
Halozyme reported revenues of $267.6 million in 2020, up 36.5% year over year. The company’s earnings in 2020 were 91 cents per share against a loss of 50 cents per share in the year-ago period.
Business Developments
During the quarter, Halozyme’s two partners — Roche and argenx — initiated two late-stage studies on their respective pipeline candidates using ENHANZE technology. Halozyme received $32 million following the initiation of these studies. Meanwhile, the European Commission approved Roche's Phesgo for the treatment of patients with early and metastatic HER2-positive breast cancer in December.
Two late-stage studies were initiated by argenx in January and February. Janssen received accelerated approval from the FDA for a combination regimen of Darzalex Faspro for the treatment of adult patients with newly diagnosed light chain ("AL") amyloidosis in the last month. Regulatory applications for subcutaneous formulation of Darzalex was submitted by Janssen to the FDA and the European Medicine Agency in November last year seeking approval as treatment for relapsed or refractory multiple myeloma in second or later-line settings.
In November, Halozyme signed a global collaboration and license agreementwith Horizon Therapeutics, granting the latter access to its ENHANZE technology to develop the SC formulation of Horizon Therapeutics’ thyroid eye disease drug, Tepezza.
2021 Guidance Issued
Halozyme issued its guidance for revenues and earnings for 2021. The company expects total revenues in 2021 to be between $375 million and $395 million, indicating year-over-year growth of 40%-48%. The company expects revenues from royalties to double year over year on the back of strong uptake of subcutaneous formulation of J&J’s Darzalex.
It expects earnings to be in the range of $1.40-$1.55 per share.
The Zacks Consensus Estimates for revenues and earnings for 2021 stands at $405.49 million and $1.62 per share, respectively. This suggests that the company’s guidance for both earnings and revenues are below market expectations.
Shares of Halozyme were down 5.7% in after-market trading on Feb 23, following the earnings miss and dismal 2021 guidance. However, the stock has gained 144.3% in the past year compared with the industry’s 11.4% increase.
Zacks Rank
Halozyme currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Halozyme Therapeutics, Inc. price-consensus-eps-surprise-chart | Halozyme Therapeutics, Inc. Quote
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>